LONDON, Nov. 16, 2016 /PRNewswire/ -- This Persistence Market Research (PMR) report examines the global cancer supportive care products market for the period 2015 - 2021. The primary objective of the report is to offer updates and information related to market opportunities in the global cancer supportive care products market.The global cancer supportive care products market report deals with cancer supportive care drugs, which can be defined as products or drugs that are mainly used for treatment of adverse effects associated with cancer therapy as well as for the treatment of the symptoms and signs of cancer drugs, such as chemotherapy-induced nausea and vomiting, chemotherapy induced neutropenia, chemotherapy-induced anemia, hair loss, etc. On the basis of drug classes, the market has been segmented into non-steroidal anti-inflammatory drugs, anti-infective, anti-emetics, monoclonal antibodies, erythropoietin stimulating agents, opioid analgesics, bisphosphonates, and granulocyte colony stimulating factors. The global cancer supportive care products market is expected to expand at a CAGR of 4.3% over the forecast period (2015-2021) to account for US$ 31,700 Mn by 2021.To understand and assess the opportunities in this market, the report is categorically split into four sections, namely market analysis by drug class, disease indication, distribution channel, and region. The report analyzes the global compounding pharmacies market in terms of market value (US$ Mn).The report starts with an overview of the global cancer supportive care products market and its usage in the treatment of various chemotherapy-associated side-effects across the globe. In the same section, PMR covers the global cancer supportive care products market performance in terms of revenue. This section includes PMR's analysis of key trends, drivers, and restraints from supply and demand perspectives.The next section of the report analyzes the market on the basis of drug class segments and presents the forecast in terms of value for all the years till 2021.Cancer supportive care products market: Drug classes covered in the report are as follows:Non-steroidal anti-inflammatory drugsAnti-infectiveAnti-emeticsMonoclonal antibodiesErythropoietin stimulating agentsOpioid analgesicsBisphosphonatesGranulocyte colony stimulating factorsThe next section of the report analyzes the market on the basis of the disease indication segments and presents the forecast in terms of value for the following six years.Cancer supportive care products market: Disease indication segments covered in the report are as followsLung cancerBreast cancerProstate cancerLiver cancerBladder cancerLeukemiaOvarian cancerMelanomaOthersPost disease indications, the following section of the report analyzes the market on the basis of distribution channels for the forecast period, in terms of value.Cancer supportive care products market: Distribution channels covered in the report are as followsHospital pharmaciesRetail pharmaciesCompounding pharmaciesThe section that follows analyzes the market on the basis of regions in terms of value for the forecast period.Cancer supportive care products market: Regions covered in the report are as follows North AmericaLatin AmericaEuropeAsia PacificThe Middle East & Africa To arrive at the market size, the report considers the market value of the global cancer supportive care products across the aforementioned geographies. The forecast presented in the report assesses the total revenue generated in the global cancer supportive care product market. When developing the market forecast, the starting point involves sizing the current market, which forms the basis for the forecast of how the market is anticipated to take shape in the near future. For this, PMR referred to several subject matter experts in the cancer supportive care products domain. Given the characteristics of the market, we triangulated the outcome based on different analysis based on the supply side, demand side, and dynamics of the market, such as regulations and GMP guidelines for cancer supportive care products. In this report, quantification of data has been conducted along with the provision of quality insights collected directly from the market through discussion with pharmacists, suppliers, physicians, and subject matter experts. This is how the market analysis for the forecast period is carried out.We have also taken into consideration the year-on-year growth of the global cancer supportive care products market, based on regional growth analysis, to understand the predictability of the market and to identify the right opportunities in it.As previously highlighted, the market for global cancer supportive care products is split into various segments on the basis of drug classes, disease indications, distribution channels, and regions. All these segments have been analyzed in terms of Basis Point Share (BPS) to understand the individual segments' relative contribution to market growth. This detailed level of information is important for identification of various key trends in the global cancer supportive care products market.Another key feature of this report is the analysis of the global cancer supportive care products market, by region, which is further segmented on the basis of countries and revenue forecast in terms of absolute dollar opportunity. Regional trends have been introspected, identified, and applied while forecasting the growth rates of the market. Additionally, the absolute dollar opportunity provided in the report is critical in assessing the level of opportunity that a provider can look to achieve from a sales perspective in the global cancer supportive care products market. In this report, PMR has also developed the market attractiveness index for all four segments, namely drug classes, disease indication, distribution channels, and regional segments. This index is intended to help in identifying the real opportunities in the market.In the final section of the report, the global cancer supportive care products market landscape is included to provide report audiences with a dashboard view, based on categories of providers in the global cancer supportive care product portfolio; their key developments and strategies have also been included wherever possible. Key market participants covered in the report are Amgen Inc., Johnson & Johnson, Novartis Ag., Baxter International Inc, Fagron Group BV, Teva Pharmaceuticals Industries Ltd, Hoffmann LA- Roche Inc., APR Applied Pharma Science Research S.A., Acacia Pharma Ltd, and Kyowa Hakko Kirin Co Ltd.